

Thermo Fisher advances biopharma discovery and development

30 October 2020 | News

Thermo Fisher and Symphogen continue work to support the development of innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows



Thermo Fisher Scientific and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical company, Servier, announce the extension of a strategic collaboration to deliver industry-proven, innovative characterization and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.

Since the collaboration was established in 2018, Symphogen has been utilizing the analytical capabilities of the [Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry \(LC-MS/MS\) system](#) with BioPharma Option, and most recently the [Thermo Scientific Orbitrap Exploris 480 mass spectrometer](#), to develop, test and routinely implement platform workflows for intact and native mass analysis of therapeutic monoclonal antibody (mAb) mixtures.

The high-performance, easy-to-use, analytical workflows were developed to enable dynamic biopharmaceutical companies like Symphogen to deliver novel treatment options for patients.